{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:14:58Z","timestamp":1778652898248,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.jocn.2011.12.026","type":"journal-article","created":{"date-parts":[[2012,6,15]],"date-time":"2012-06-15T15:23:12Z","timestamp":1339773792000},"page":"1490-1496","source":"Crossref","is-referenced-by-count":49,"title":["A longitudinal study of sensory biomarkers of progression in patients with diabetic peripheral neuropathy using skin biopsies"],"prefix":"10.1016","volume":"19","author":[{"given":"H.","family":"Narayanaswamy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Facer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.P.","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Byttebier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Meert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2011.12.026_b0005","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1212\/WNL.43.4.817","article-title":"The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study","volume":"43","author":"Dyck","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2011.12.026_b0010","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/diacare.16.11.1446","article-title":"Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population","volume":"16","author":"Harris","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jocn.2011.12.026_b0015","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2011.12.026_b0020","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2011.12.026_b0025","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ana.410380607","article-title":"The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial","volume":"38","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2011.12.026_b0030","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.51.3.695","article-title":"Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group","volume":"51","author":"Apfel","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2011.12.026_b0035","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.284.17.2215","article-title":"Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group","volume":"284","author":"Apfel","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jocn.2011.12.026_b0040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1046\/j.1529-8027.2001.01019.x","article-title":"A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy","volume":"6","author":"Wellmer","year":"2001","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.jocn.2011.12.026_b0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0079-6123(03)46030-5","article-title":"Neurotrophic factors and their receptors in human sensory neuropathies","volume":"146","author":"Anand","year":"2004","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.jocn.2011.12.026_b0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0006-8993(94)90252-6","article-title":"Nerve growth factor administration protects against experimental diabetic sensory neuropathy","volume":"634","author":"Apfel","year":"1994","journal-title":"Brain Res"},{"key":"10.1016\/j.jocn.2011.12.026_b0055","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0092-8674(94)90048-5","article-title":"Functions of the neurotrophins during nervous system development: what the knockouts are teaching us","volume":"77","author":"Snider","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.jocn.2011.12.026_b0060","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2337\/dc06-2479","article-title":"Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity","volume":"30","author":"Dyck","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jocn.2011.12.026_b0065","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.2337\/dc07-0608","article-title":"Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials","volume":"30","author":"Tesfaye","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jocn.2011.12.026_b0070","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1212\/WNL.60.1.108","article-title":"The spectrum of neuropathy in diabetes and impaired glucose tolerance","volume":"60","author":"Sumner","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2011.12.026_b0075","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2337\/diacare.24.8.1448","article-title":"Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy","volume":"24","author":"Singleton","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jocn.2011.12.026_b0080","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/mus.1137","article-title":"The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy","volume":"24","author":"Novella","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2011.12.026_b0085","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2337\/dc06-0224","article-title":"Lifestyle intervention for pre-diabetic neuropathy","volume":"29","author":"Smith","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jocn.2011.12.026_b0090","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm0696-703","article-title":"The role of endogenous nerve growth factor in human diabetic neuropathy","volume":"2","author":"Anand","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.jocn.2011.12.026_b0095","unstructured":"P.J. Dyck, Severity and staging of polyneuropathy. In: Gries FA, Cameron NE, Low PA, et al., editors. Text book of diabetic neuropathy. New York: Thieme; 2003. p. 170\u201374."},{"key":"10.1016\/j.jocn.2011.12.026_b0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000052074","article-title":"NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy","volume":"41","author":"Bril","year":"1999","journal-title":"Eur Neurol"},{"key":"10.1016\/j.jocn.2011.12.026_b0105","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0304-3959(87)91074-8","article-title":"The short-form McGill Pain Questionnaire","volume":"30","author":"Melzack","year":"1987","journal-title":"Pain"},{"key":"10.1016\/j.jocn.2011.12.026_b0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2377-7-21","article-title":"Use of the novel Contact Heat Evoked Potential Stimulator (CHEPS) for the assessment of small fibre neuropathy: correlations with skin flare responses and intra-epidermal nerve fibre counts","volume":"7","author":"Atherton","year":"2007","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jocn.2011.12.026_b0115","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1054\/jocn.2001.0893","article-title":"The natural history of diabetic peripheral neuropathy determined by a 12year prospective study using vibration perception thresholds","volume":"8","author":"Coppini","year":"2001","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jocn.2011.12.026_b0120","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.2337\/diacare.27.12.2930","article-title":"The LDIflare: a novel test of C-fiber function demonstrates early neuropathy in type 2 diabetes","volume":"27","author":"Krishnan","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jocn.2011.12.026_b0125","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.clinph.2010.02.159","article-title":"The time course of CO2 laser-evoked responses and of skin nerve fibre markers after topical capsaicin in human volunteers","volume":"121","author":"Rage","year":"2010","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.jocn.2011.12.026_b0130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0304-3959(99)00273-0","article-title":"Do nerve growth factor-related mechanisms contribute to loss of cutaneous nociception in leprosy?","volume":"85","author":"Facer","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.jocn.2011.12.026_b0135","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/brain\/121.12.2239","article-title":"Correlation of quantitative tests of nerve and target organ dysfunction with skin immunohistology in leprosy","volume":"121","author":"Facer","year":"1998","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2011.12.026_b0140","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-6874-5-2","article-title":"Increased capsaicin receptor TRPV1 in skin nerve fibres and related vanilloid receptors TRPV3 and TRPV4 in keratinocytes in human breast pain","volume":"5","author":"Gopinath","year":"2005","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.jocn.2011.12.026_b0145","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.57.9.1701","article-title":"Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy","volume":"57","author":"Smith","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2011.12.026_b0150","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1212\/WNL.47.4.1042","article-title":"Quantitation of epidermal nerves in diabetic neuropathy","volume":"47","author":"Kennedy","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2011.12.026_b0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2377-7-11","article-title":"Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy","volume":"7","author":"Facer","year":"2007","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jocn.2011.12.026_b0160","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/brain\/awh175","article-title":"The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy","volume":"127","author":"Polydefkis","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2011.12.026_b0165","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/brain\/awh180","article-title":"Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments","volume":"127","author":"Shun","year":"2004","journal-title":"Brain"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586812002007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586812002007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T14:24:31Z","timestamp":1542896671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586812002007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0967586812002007"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2011.12.026","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}